WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318970

CAS#: 137862-53-4

Description: Valsartan is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor. Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack. Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.

Price and Availability


USD 150
USD 650
USD 1650

USD 250
USD 850
USD 1950

USD 450
USD 1250
USD 3650

Valsartan, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Note: the estimated shipping out time for order > 100 g may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318970
Name: Valsartan
CAS#: 137862-53-4
Chemical Formula: C24H29N5O3
Exact Mass: 435.22704
Molecular Weight: 435.528
Elemental Analysis: C, 66.19; H, 6.71; N, 16.08; O, 11.02

Related CAS #: 936623-90-4   137862-53-4   149690-05-1 (sodium)  

Synonym: CGP48933, CGP-48933, CGP 48933, Valsartan, Diovan, Miten, Nisis, Prova, Tareg, Vals, Walsartan

IUPAC/Chemical Name: (S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid


InChi Code: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1


Technical Data

White to off-white crystalline powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Lillyblad MP. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14. Review. PubMed PMID: 26175499.

2: Ardiana F, Suciati, Indrayanto G. Valsartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:431-93. doi: 10.1016/bs.podrm.2015.01.004. Epub 2015 Mar 21. Review. PubMed PMID: 26051690.

3: Janić M, Lunder M, Šabovič M. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. Epub 2015 Mar 3. Review. PubMed PMID: 25821790; PubMed Central PMCID: PMC4363554.

4: Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015 Apr;16(5):763-70. doi: 10.1517/14656566.2015.1020790. Review. PubMed PMID: 25747524.

5: Güleç S. Valsartan after myocardial infarction. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S9-13. doi: 10.5152/akd.2014.00002. Review. PubMed PMID: 25604205.

6: Kızılırmak P, Üresin AY. Hypertension and valsartan. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S20-4. doi: 10.5152/akd.2014.00004. Review. PubMed PMID: 25604204.

7: Ecder T. Renal and metabolic effects of valsartan. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S14-9. doi: 10.5152/akd.2014.00003. Review. PubMed PMID: 25604203.

8: Kılıçkıran Avcı B, İkitimur B, Karadağ B, Öngen Z. Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S1-8. doi: 10.5152/akd.2014.00001. Review. PubMed PMID: 25604202.

9: Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control. 2014 Nov 26;7:61-70. doi: 10.2147/IBPC.S50954. eCollection 2014. Review. PubMed PMID: 25473311; PubMed Central PMCID: PMC4251532.

10: Lawrence Gould A, Unniachan S, Wu D. Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. Int J Clin Pract. 2014 Feb;68(2):163-72. doi: 10.1111/ijcp.12343. Review. PubMed PMID: 24460615.

11: Huang QF, Li Y, Wang JG. Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients. Drug Des Devel Ther. 2013 Dec 30;8:79-86. doi: 10.2147/DDDT.S38617. Review. PubMed PMID: 24403822; PubMed Central PMCID: PMC3883632.

12: Ferdinand KC, Nasser SA. A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension. Am J Cardiovasc Drugs. 2013 Oct;13(5):301-13. doi: 10.1007/s40256-013-0033-4. Review. PubMed PMID: 23784267; PubMed Central PMCID: PMC3781303.

13: Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7. doi: 10.1517/13543784.2013.797963. Epub 2013 May 10. Review. PubMed PMID: 23663006.

14: Volpe M. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert Rev Cardiovasc Ther. 2012 Aug;10(8):1061-72. doi: 10.1586/erc.12.80. Review. PubMed PMID: 23030295.

15: Benge CD, Muldowney JA 3rd. The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1469-82. doi: 10.1517/17425255.2012.725721. Epub 2012 Sep 24. Review. PubMed PMID: 22998368.

16: Lacourcière Y. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review. Clin Exp Hypertens. 2013;35(1):50-60. doi: 10.3109/10641963.2012.690468. Epub 2012 Aug 6. Review. PubMed PMID: 22866964.

17: Miura S, Saku K. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine. J Int Med Res. 2012;40(1):1-9. Review. PubMed PMID: 22429340.

18: Sestito A. Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan. Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1247-55. Review. PubMed PMID: 22195356.

19: Maksimov ML, Mochkin IA, Starodubtsev AK. [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice]. Kardiologiia. 2011;51(8):77-84. Review. Russian. PubMed PMID: 21942964.

20: Bains J, Smith WB. Valsartan plus hydrochlorothiazide: a review of its use since its introduction. Expert Opin Pharmacother. 2011 Aug;12(12):1975-84. doi: 10.1517/14656566.2011.587124. Epub 2011 Jul 6. Review. PubMed PMID: 21728903.